Worg Biotherapeutics
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Global biopharma company developing molecular allergy immunotherapies using proprietary platforms, with commercial products in Europe and clinical programs advancing worldwide.
Immunology
Technology Platform
PCFiT™ platform for molecular allergy immunotherapy development and Apitope® peptide-based technology platform designed to induce immune tolerance for allergic and autoimmune diseases.
Opportunities
Large and growing global allergy/autoimmune disease markets, particularly in Asia; shift toward precision molecular immunotherapies; established European commercial footprint provides revenue base and regulatory pathway experience.
Risk Factors
Clinical development risks for novel immunotherapies; operational complexity of dual China-Europe structure; competition from larger pharma and biotech companies in immunology; regulatory hurdles in key markets like China and EU.
Competitive Landscape
Competes with allergy immunotherapy companies like ALK-Abelló, Stallergenes Greer, and emerging biotechs in peptide immunotherapy; differentiation through comprehensive four-generation AIT technology coverage and integrated global diagnostics-therapeutics approach.